Evidence suggests that IGF and their binding proteins play a role in fetal growth, but more knowledge concerning their regulation is essential. We examined the expression of IGF and their binding proteins in experimental intrauterine growth-retarded (IUGR) rat fetuses of hypoxic dams (13-14% oxygen, d 14-21 of gestation). The mean body weight of the fetuses (d 21 of gestation, tz = 72) of the six hypoxic dams was 24% lower @ < 0.0001) than the mean weight of the fetuses of six control dams (11 = 82). Wet liver weights demonstrated a 20% decrease @ < 0.0001) and placentas a 10% decrease @ < 0.01) compared with control fetuses. The mean serum concentrations of immunoreactive IGF-I in both groups were low but did not differ significantly. The mean serum concentrations of immunoreactive IGF-11. however, were higher in IUGR fetuses. As assessed by Northern blot analysis, there was a 4-fold increase in insulin-like growth factor binding protein-1 (IGFBP-I) mRNA expression in the livers of the IUGR fetuses compared with controls. IGFBP-2 mRNA expression was 6-fold increased Evidence suggests that IGF and their binding proteins play a role in the regulation of fetal growth and development, but more knowledge of their interaction is essential. In the rat, gene expression for IGF-I1 is high in many fetal tissues, and high levels of IGF-I1 are also found in fetal serum (1). The finding that fetal IGF-I1 concentrations are elevated, rather than reduced, in growth retardation suggests that IGF-I1 has a function in assisting in the metabolic adaptation of the fetus to the growthin IUGR fetal livers. N o difference was found in IGFBP-4 mRNA. An increase in IGFBP-I, -2, and -4 concentrations could be seen by Western ligand blotting in the serum of growth-retarded fetuses compared with control fetuses. This finding was verified by immunoprccipitation with specific antibodies, which demonstrated increases in IGFBP-I and IGFBP-2. Our results validate the use of maternal hypoxia as an experimental model of intrauterine growth retardation and indicate that increased IGFBP-1 and -2 expression may be of importance in the etiology of fetal growth retardation caused by maternal hypoxia. (2) . The gene for IGF-1 is also expressed in a variety of fetal tissues, but at lower levels than the gene for IGF-I1 (3). IUGR in different animal models has been shown to be associated with decreased IGF-I concentrations (4-7), suggesting that fetal serum IGF-I could be a valuable marker for intrauterine substrate deprivation. O n the other hand, there are studies that fail to demonstrate any difference in IGF-I levels between short-term hypoxic and normal ovine fetuses @).The actions of IGF are modulated by specific IGFBP. To date, six distinct IGFBP have been identified and their cDNA cloned and the IGFBP-2 gene in retarded fetal growth. It has been shown to be increased (13) and unchanged (5, 12) . Hypoxia for 24 h induced by the reduction of maternal uterine blood flow was recently shown to decrease the expression of IGBP-2 in ovine fetuses (8). The etiology of IUGR can be either genetic or acquired. Mechanical late constraint has been emphasized as perhaps the most common cause of IUGR. Clinically, most fetal growth retardation states are associated with inadequate supply of both oxygen and nutrients to the fetus. Experimental models of growth retardation have generally used either interference with placental function (2) or uterine blood flow (6, 12, 13) or limitation of maternal energy and protein intake to restrict fetal growth (5, 7, 14) . We have used maternal hypoxia as a model for IUGR and have studied its effect on IGF and their binding proteins to clarify their role in retarded fetal growth.
METHODS
AnimaLF and study design. Timed pregnant SpragueDawley rats (rt = 12) were obtained from Simonsen Breeding Colonies (Gilroy, CA). IUGR was induced by exposure of the dams (n = 6) to 13-14% oxygen between d 14 and 21 of gestation, as previously described (15) . Special environmental chambers were designed for this purpose. At lower oxygen saturations (9.5-11%), increased fetal wastage was observed, with a reduction in litter size from 13 to eight. Six additional dams served as controls and were exposed to 21% oxygen in similar environmental chambers. The rats were maintained with standard lighting (lights on 0500-1900 h daily) and temperature (26°C) under standard vivarium conditions approved by the American Association for Accreditation of Laboratory Animal Care. Tap water and food were available ad libitum. There was no significant difference in food consumption between the study groups (data not shown).
On d 21, a cesarean section was performed under ketamine and xylazine anesthesia. Fetuses were removed from the uterus, weighed, and killed by decapitation. Blood was collected from the cervical stumps, allowed to clot at 4°C for 30 min, and centrifuged at 10 000 rpm for 15 min to separate serum. The serum samples were stored at -20°C until analyzed. Livers were quickly removed, weighed, frozen in liquid nitrogen within 5 min of decapitation, and subsequently stored at -70°C. These studies were approved by The Ethical Animal Committee of Stanford University School of Medicine.
IGF peptides and IGFBP antibodies. Pure biosynthetic IGF-I was purchased from Bachem (Philadelphia, PA). Recombinant IGF-I1 was generously provided by Dr. Michele Smith (Lilly Research Laboratories, Indianapolis, IN). The peptides were iodinated by a modification of the chloramine-T technique to specific activities of 150-250 ~C i l~g .
Rabbit polyclonal antiserum aHEC, raised against IGF-I1 affinity-purified medium from a human endometrial carcinoma cell line, specifically recognizes rat IGFBP-2 and does not cross-react with rlGFBP-3, as previously described (16) . Antiserum against rat IGFBP-1 was prepared as previously described ( 17) .
IGF-I and IGF-I1 RIA. Serum samples were chromatographed in 0.25 M formic acid on a 0.9 x 100-cm column of Sephadex G-50 (Pharmacia Fine Chemicals, Piscataway, NJ). The fractions eluting between 50 and 67 mL, which contain 90% of the IGF activity and no demonstrable IGFBP, were collected in glass tubes containing 1.0 mL of 1% BSA and were subsequently frozen and lyophilized. Serum IGF-I was measured by RIA, using [ 1 2 5~]~G~-~ as radioligand and a polyclonal anti-IGF-I antibody. This antiserum (UBK487) was a generous gift from the hormone distribution program of the National Institute of Diabetes and Digestive and Kidney Diseases and was originally provided by Drs. J. J. Van Wyk and L. E. Underwood (University of North Carolina). Serum IGF-I1 was measured by RIA using [ ' 2 S~]~~~-~~ as a radioligand and an MAb against rat IGF-I1 (Amano Enzyme Co., Inc., Troy, VA). The detection limits of the assays for IGF-I and -11 were 0.1 and 0.5 ng/mL, respectively, and the interassay coefficients of variation were 13.3 and 16.376, respectively. Western ligand blotting. Analysis of IGFBP in fetal serum by Western ligand blotting was performed as originally described by Hossenlopp et a/. (18) with minor modifications. Briefly, SDS-PAGE was performed according to the methods of Laemmli (19) in a 12% polyacrylamide gel with a 4% stacking gel. Twenty FL of 1:10 diluted serum were applied per lane, and prestained molecular weight markers (BRL, Bethesda, MD) were run in parallel lanes. After electrophoresis, the IGFBP were transferred to nitrocellulose (0.45-pm pore size) in a Hoeffer Semi-dry Transphor unit (San Francisco, CA) at 200 mA. The filters were blocked with 1% BSA, as described earlier (18), before an overnight incubation at 4°C with approximately 1.5 x 10" cpm of a mixture of equal amounts of [ 1 2 S~]~~~-~ and [ 1 2 5~]~~~-~~. Thereafter, filters were washed with 0.1 % Tween 20 in Tris-buffered saline for 20 min and 120 min, air dried, and exposed to Kodak X-Omat AR film (Eastman Kodak, Rochester, NY) for 4 d at -70°C.
Immunoprecipitation. Serum IGFBP were immunoprecipitated using specific IGFBP antibodies. Five p L of fetal serum and 5 p L of the undiluted antiserum (a-HEC or a-IGFBP-1) were mixed with 40 p L of N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid and incubated overnight at 4OC. The IGFBP-antibody complexes were precipitated by addition of 50 p L of Pansorbin and incubation for 4 h at 20°C. The pellets were washed three times with N-2-hydroxyethylpiperazine-N1-2-ethanesulfonic acid and, after the addition of nonreducing SDS sample buffer, the pellets were boiled for 5 min. The supernatants were processed for Western ligand blotting as described above.
RNA isolation and Northern blot analysis. Total cellular RNA was isolated from liver tissues using the modified guanidine thiocyanate cesium chloride method as previ-ously described (20) . Total RNA (20 pg) was size fractionated in a 1.2% agarose-formaldehyde gel, stained with ethidium bromide (1 pg/mL for 5 min), and transferred to nitrocellulose (0.45-pm pore size). An RNA ladder (BRL, Gaithersburg, MD) was run in parallel with the samples to allow sizing of the mRNA. The nitrocellulose filters were photographed in UV light, and the ethidium bromide-stained 18 S RNA bands were used to reflect the total amount of RNA loaded in each lane. The filters were then hybridized with rat cDNA for IGFBP-1 and IGFBP-2 and a human cDNA for IGFBP-4, according to the method of Wahl et al. (21) , and exposed to Kodak X-Omat AR film with an intensifying screen at -70°C for 4 1 4 d.
The cDNA probe for rat IGFBP-1 was a 350-bp HindIII-EcoRI insert of a fragment isolated from a rat decidual cDNA library (22) . The probe for rat IGFBP-2 was a 1295-bp EcoRI restriction fragment of a 1500-bp cDNA isolated from a rat liver cDNA library and contained the entire coding region (23) . The probe for human IGFBP-4 was a 440-bp SmaI restriction fragment of the 1.2-kb cDNA isolated from a human osteosarcoma cell gene library (24) . These cDNA were generously provided by Drs. L. Murphy, J. Schwander (Basel, Switzerland) and S. Mohan (Loma Linda, CA), respectively. The probes were labeled with ["PI~CTP (Arnersham Co., Arlington Heights, IL) by random priming, using a commercial kit (Pharmacia, Uppsala, Sweden).
Quantc$cation of autoradiograms. The relative levels of IGFBP and mRNA on autoradiograms of Western ligand blots and Northern blots, respectively, were quantified by laser densitometry (Ultrascan XL, LKB, Bromma, Sweden). The relative densities of the bands were expressed as arbitrary absorbance units per mm.
Calculations and statistical analysis. Western ligand blotting of plasma samples and Northern analysis of total RNA samples from livers of control and IUGR fetuses were all performed a minimum of three times. Statistical significance between the two groups of animals was calculated using the t test. The results are expressed as mean + SD.
RESULTS

Somatic growth.
Maternal hypoxia resulted in IUGR, which was reflected by a significant decrease in fetal weight. The mean body weight of the fetuses (n = 72) from the hypoxic dams (n = 6) was 24% lower @ < 0.0001) than the mean weight of the fetuses (n = 82) of the control dams (n = 6). Wet liver weights of hypoxic fetuses demonstrated a 20% decrease @ < 0.001) and placentas a 10% decrease @ < 0.01) compared with control fetuses (Fig. 1) . The mean litter size did not differ significantly between the groups (12 f 1.1 and 14 f 0.8, respectively).
Serum IGF. The mean serum concentration of ir-IGF-I, determined from the pooled sera of all the fetuses of one dam, was low in both groups (54 f 7 pg/L in IUGR C H C H Placenta Liver fetuses and 59 f 9 kg/L in control fetuses), but there was no significant difference between the groups. The mean concentrations of ir-IGF-I1 were high: 418 f 33 pg/L in the IUGR fetuses, and 297 f 31 pg/L in the control fetuses. The IGF-I1 values thus tended to be higher in the IUGR group, with the difference just reaching significance (p = 0.05). Serum IGFBP. Figure 24 shows the Western ligand blot of IGFBP of IUGR and control fetuses of each dam. Each lane represents the pooled sera of all the fetuses of one dam. The comparison of relative quantities of different IGFBP, as determined by densitometry, is shown in Figure 2B . Western ligand blotting of the sera showed a very weak 38-to 44-kD band, representing rIGFBP-3; a distinct 28-kD band consisting of rIGFBP-1 and rIGFBP-2 (see below); and a 24-kD band, tentatively identified as rIGFBP-4. Compared with control fetuses, the 28-kD band was 1.75-fold more intense in the IUGR fetuses (p < 0.001). The 24-kD band was also more intense (2.5-fold) in the IUGR fetuses compared with controls (p < 0.001). The 28-kD band was shown to consist of both IGFBP-1 and IGFBP-2 by immunoprecipitation with specific antisera against IGFBP-1 or IGFBP-2 (Fig. 3) . It was not possible, however, to completely resolve the 28-kD band, although immunoprecipitation studies suggest that both IGFBP-1 and IGFBP-2 are increased in hypoxic fetuses. This conclusion is supported by mRNA studies (see below).
Tissue IGFBP mRNA levels. The effect of maternal hypoxia on IGFBP-1, IGFBP-2, and IGFBP-4 mRNA levels in hypoxic and control fetuses is shown in Figure 4 . 
DISCUSSION
We used maternal hypoxia as an experimental model for IUGR and observed 24% growth retardation in 21-dold fetuses, without significant fetal wastage. This is in agreement with other studies in which maternal hypoxia has been used to retard fetal growth and in which the percent retardation of fetal weight varied between 13 and 36%, depending on the oxygen concentration and length of exposure to hypoxia (25, 26) . The observed growth retardation was comparable to that observed with other IGFBP-1 mRNA in the fetal liver consisted predominantly of a major species of 1.8 kb; one minor species of 4.0 kb was also observed. IGFBP-1 mRNA levels were increased approximately 4-fold in the IUGR fetuses compared with fetuses from control dams. IGFBP-2 mRNA in fetal livers consisted of one major band of 1.6 kb. Maternal hypoxia was also found to have an inducing anism by which maternal hypoxia causes IUGR differs from that of maternal fasting. No difference was found in the maternal food intake in our model, so the role of nutrient availability plays a minor role in the hypoxia model. However, maternal hypoxia has some similarities with the ligation of uterine artery model, in which there is graded reduction in uterine blood flow. Both models lead to centralization of blood flow in favor of the brain, heart, and adrenals at the expense of almost all peripheral organs. This response has been shown to be qualitatively similar but quantitatively different between the models (28) . Although all of the experimental models described subunit above have produced useful information, none of them are totally satisfactory. Surgical approaches for determining hormonal regulation of fetal growth are invasive and technically difficult because of the small size of most laboratory animals. Furthermore, it has been shown that any type of surgical invasion of the uterus results in nonspecific growth inhibition of rat fetuses (29) . Our model has some similarities with the situation observed in humans living at high altitude, where the mean birth weight of babies has been shown to be lower than the weight of those born at sea level, as well as with IUGR fetuses of rhesus isoimmunized mothers (30, 31) , especially because the hypoxia model does not include any surgical intervention and results in significant growth retardation without invasive methods. Although it results in IUGR, it may not be the best model for evaluation of placental insufficiency as a cause of fetal growth retardation. Although the mean weight of the placentas was reduced by 1070, the etiology of fetal growth failure in hypoxia may be different from that observed with primary placental inadequacy.
We could not detect any significant difference in ir-IGF-I levels between hypoxic and control fetuses, which suggests that total circulating IGF-I levels do not explain the growth retardation seen in this model. Our results are in contrast to those of maternal malnutrition studies, in which circulating IGF-I levels were decreased and speculated to cause IUGR (5, 7, 14) . On the other hand, restriction of maternal blood flow for 24 h did not influence circulating IGF-I levels in ovine fetuses, suggesting that hypoxia probably causes IUGR by other mechanisms, which is in agreement with our findings (8). Although the biologic role of IGF-I in postnatal growth is well established, there is still some controversy concerning its role as a fetal growth factor in the rat, despite the fact that many fetal rat tissues synthesize IGF-I mRNA (32) . In contrast, evidence strongly suggests that IGF-I1 is an important regulator of growth during fetal life (33, 34) and may even have a function in assisting in the metabolic adaptation of the fetus to the growth-retarded state (2) . In the present study, the levels of ir-IGF-I1 were higher in IUGR fetuses, which is in agreement with the results of the study of Jones et al. (2) . The concentrations of IGF-11 in serum are known to decrease rapidly to very low levels after birth (35) , as does the level of expression of the IGF-I1 gene. It is possible that the hypoxic fetuses are developmentally delayed compared with control fetuses, and therefore they retain higher IGF-I1 levels. It can also be speculated that increased levels of IGFBP-1 and -2 provide an increased IGF-11 binding capacity. However, inasmuch as tissue IGF-I1 mRNA levels were not determined, this cannot be proved by the present study. In the growth-retarded fetuses, we demonstrated an increase in the 28-kD IGFBP, which, by immunoprecipitation, clearly consisted of both IGFBP-1 and -2. Northern blot studies indicated increased mRNA for both IGFBP, and it is likely that Western ligand blot data reflect a rise in protein level as well. The 1.75-fold increase in serum IGFBP-1 and -2 levels, supported by immunoprecipitation with specific antibodies, was accompanied by a 4-fold increase in liver IGFBP-1 mRNA and a 6-fold increase in IGFBP-2 mRNA, suggesting that both IGFBP-1 and IGFBP-2 are associated with retarded fetal growth. It has been previously shown that both IGFBP-1 and -2 mRNA are expressed at high levels in liver of 21-d gestation rats (36) . It has been speculated that IGFBP-1 is involved in the regulation of fetal growth, based on the fact that IGFBP-1 levels have been increased in some experimental IUGR models in the rat ( 5 , 12, 13, 17) . There is also evidence in human fetuses concerning the importance of IGFBP-1 in the fetal growth-retarded state. IGFBP-I levels, as determined by RIA in umbilical cord serum, have been shown to be higher in small-for-gestational-age babies compared with average-for-gestational-age infants (37) (38) (39) . In contrast, the data concerning changes in IGFBP-2 in growthretarded states are conflicting. Increased (13) and unchanged (5, 12) levels have been reported, depending on the experimental model used. These different results may reflect the different models of IUGR used or the lack of specific antibodies to detect individual IGFBP. It is therefore of note that in our model of IUGR changes in serum IGFBP levels were reflected by parallel changes in mRNA (Table 1) . Insulin is proposed to be an important regulator of IGFBP-1, and there is generally an inverse relationship between the two (4042). IUGR after bilateral uterine artery ligation results in increased levels of both circulating IGFBP-1 and hepatic IGFBP-1 mRNA but a decrease in fetal insulin and glucose (12, 17). The mechanism by which maternal hypoxia causes increased IGFBP-I expression may also be related to hypoinsulinemia. We were not able to measure serum insulin levels because of the limited quantities of serum obtained from these fetuses, but decreased serum insulin is well described in ever, indicate that IGFBP-1 and IGFBP-2 are similarly regulated in the maternal hypoxia model of fetal growth failure. Although there is now considerable evidence that IGF and IGFBP play a role in the control of fetal growth, the precise mechanism by which fetal growth is regulated is still uncertain. Whether the increases in IGFBP-1 and IGFBP-2 represent the process or the result of IUGR produced by maternal hypoxia remains to be investigated. It is possible that when the relative amounts of IGFBP-I and IGFBP-2 in the fetus increase, the net binding capacity of fetal serum for IGF peptides also rises. This may be of particular importance in the fetal rat, where serum levels of IGFBP-3 are low (44) . The rise in serum IGFBP may restrict the availability of IGF peptides to fetal tissues and thereby reduce fetal growth. We conclude that our results validate the use of maternal hypoxia as an experimental model of IUGR and indicate that increased IGFBP-1 and-2 expression may be of importance in the etiology of fetal growth retardation.
